GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Interest Coverage

Rising Biosciences (Rising Biosciences) Interest Coverage : 0 (At Loss) (As of . 20)


View and export this data going back to . Start your Free Trial

What is Rising Biosciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Rising Biosciences's Operating Income for the three months ended in . 20 was $0.00 Mil. Rising Biosciences's Interest Expense for the three months ended in . 20 was $0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Rising Biosciences's Interest Coverage or its related term are showing as below:


RBII's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.39
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Rising Biosciences Interest Coverage Historical Data

The historical data trend for Rising Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Rising Biosciences Interest Coverage Chart

Rising Biosciences Annual Data
Trend
Interest Coverage

Rising Biosciences Quarterly Data
Interest Coverage

Competitive Comparison of Rising Biosciences's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rising Biosciences's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Interest Coverage falls into.



Rising Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rising Biosciences's Interest Coverage for the fiscal year that ended in . 20 is calculated as

Here, for the fiscal year that ended in . 20, Rising Biosciences's Interest Expense was $0.00 Mil. Its Operating Income was $0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Rising Biosciences had no debt (1).

Rising Biosciences's Interest Coverage for the quarter that ended in . 20 is calculated as

Here, for the three months ended in . 20, Rising Biosciences's Interest Expense was $0.00 Mil. Its Operating Income was $0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Rising Biosciences had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Rising Biosciences  (GREY:RBII) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Rising Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Rising Biosciences (Rising Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1180 Cleveland Road, Sandusky, OH, USA, 44870
Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.

Rising Biosciences (Rising Biosciences) Headlines

From GuruFocus

PAOG Officially Appoints Karl Riedel as New CEO and President

By Marketwired Marketwired 02-11-2019

Rising Biosciences Set To Acquire All Assets from PAO Group

By Marketwired Marketwired 11-07-2018